State Street SPDR S&P Pharmaceuticals ETF
XPH
76 hedge funds and large institutions have $271M invested in State Street SPDR S&P Pharmaceuticals ETF in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 33 reducing their positions, and 13 closing their positions.
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
1% less funds holding
Funds holding: 77 → 76 (-1)
15% less capital inflows, than outflows
Capital inflows: $65.5M | Capital outflows: $77.1M
37% less call options, than puts
Call options by funds: $520K | Put options by funds: $824K
45% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$25.8M |
| 2 |
Psagot Value Holdings
Tel Aviv,
Israel
|
+$12.2M |
| 3 |
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet
Tel Aviv,
Israel
|
+$5.48M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.08M |
| 5 |
LPL Financial
San Diego,
California
|
+$3.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19.6M |
| 2 |
Mather Group
Chicago,
Illinois
|
-$13.8M |
| 3 |
HF
Hoxton Financial
Shepherdstown,
West Virginia
|
-$8.27M |
| 4 |
Citigroup
New York
|
-$5.21M |
| 5 |
Stephens Inc
Little Rock,
Arkansas
|
-$4.6M |
XPH Hedge Fund Activity: Q4 2015 in Review
76 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2015, worth a combined $271M — up 3.7% from $261M a quarter earlier.
Fund positioning in XPH was balanced in Q4 2015: 13 funds opened new positions, 13 closed out, 18 added to existing stakes and 33 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $25.8M. The largest seller was Susquehanna International Group, cutting an estimated $19.6M.
- 76 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2015, down from 77 in Q3 2015.
- Funds reported $271M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2015, up 3.7% quarter-over-quarter.
- 13 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2015 and 13 closed out, a net change of 0 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2015 was Goldman Sachs, an estimated $25.8M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2015 was Susquehanna International Group, an estimated $19.6M sold.
Based on aggregated 13F filings for Q4 2015.